Orion signs $16 million deal with Jemincare for development of novel non-opioid pain treatment

May 13, 2022

Eli Lilly’s Blood Cancer Drug Gets FDA Green Light

February 8, 2023

Gilead’s Trodelvy lung cancer trial fails to increase survival, leading to a sell-off

January 25, 2024

Must Read

Zealand’s obesity medication fails once more in phase 3

October 9, 2026

BD Plans Huge U.S. Investment to Expand Medical Manufacturing

October 9, 2026

Phase 3 Firmonertinib Study Misses Primary Endpoint in EGFR Exon 20 NSCLC

October 9, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Novo Launches Late-Stage Trial of Lower-Dose Wegovy Pill for Weight Management

Oregon Study Finds Triple-Drug Regimen Kept Infant Macaques HIV-Free for One Year

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Zealand’s obesity medication fails once more in phase 3

Phase 3 Firmonertinib Study Misses Primary Endpoint in EGFR Exon 20 NSCLC

Pfizer Reports Phase 3 Results for Litfulo and Phase 2 Atopic Dermatitis Data for Tilrekimig

Mirum’s Brelovitug Meets Main Goal in Phase 3 Chronic Hepatitis Delta Trial

Novartis agrees to pay Abogen $7.8 billion for its in vivo autoimmune T-cell engager

Merck anticipates a significant win for the $3 billion eye disease opportunity

Novo and Lilly Trade New GLP-1 Data at Major Diabetes Meeting

Suki Launches AI Dictation Tool Integrated With Epic and Meditech EHRs

Claryx Appears From Stealth to Deal with the $45B Hospital-Acquired Infections Issue

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

How Healthcare Organizations Are Building AI Centers of Excellence

The Rise of Platform Biotech Companies

Top 10 Emerging Modalities Beyond RNA Therapeutics

Top 10 ESG Priorities for Life Sciences Companies

Tag: Zealand’s obesity

Zealand’s obesity medication fails once more in phase 3

Editor Picks

Orion signs $16 million deal with Jemincare for development of novel non-opioid pain treatment

Eli Lilly’s Blood Cancer Drug Gets FDA Green Light

Gilead’s Trodelvy lung cancer trial fails to increase survival, leading to a sell-off

Must Read

Zealand’s obesity medication fails once more in phase 3

BD Plans Huge U.S. Investment to Expand Medical Manufacturing

Phase 3 Firmonertinib Study Misses Primary Endpoint in EGFR Exon 20 NSCLC

Hot Topics

About Us

Follow Us